MRK - TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback
- TherapeuticsMD’s $177 million buyout deal with EW Healthcare largely undervalues the biotech.
- TherapeuticsMD is close to stimulating the commercialization of Annovera which may increase its value as a standalone company in the long run.
- Shareholders were informed of a 50:1 reverse stock split at the end of Q1 2021 just a few days before the buyout was announced.
- Investors are in support of the acquisition due to TherapeuticsMD's poor financial position but insist on better terms including an expanded bidding process.
For further details see:
TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback